2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Alex Duval, MD, PhD, discusses the use of microsatellite instability–high as a biomarker of response to therapy in patients with cancer.
Alex Duval, MD, PhD, professor of molecular oncology, director, Instability of Microsatellites and Cancer team, Saint-Antoine Research Center, French Institute of Health and Medical Research, discusses the use of microsatellite instability–high (MSI-H) as a biomarker of response to therapy in patients with cancer.
As a biomarker of response, MSI-H can influence and guide clinical treatment decisions, says Duval. Moreover, MSI status may be the first indication that giving immunotherapy with checkpoint inhibitors is warranted in a particular patient.
Currently, using MSI status to inform immunotherapy initiation is commonly used in the metastatic setting. However, this concept will likely be applied to the non-metastatic to inform response other drugs such as chemotherapy.
Notably, this applies to a host of therapies, including chemotherapy. For example, it is now understood that patients with gastric cancer who are MSI-H will not respond to chemotherapy, Duval concludes.